Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours

Breast Cancer Clinical Trial

— FGFR  

Official title:

Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01795768
• Other study ID #: 3689
• Status: Recruiting
• Phase: Phase 2
• First received: January 31, 2013
• Last updated: March 14, 2013
• Start date: September 2012
• Est. completion date: September 2015

Study information

• Verified date: March 2013
• Source: Royal Marsden NHS Foundation Trust
• Contact: Angela Gillbanks
• Phone: +44(0)2086613156
• Email: angela.gillbanks[@]rmh.nhs.uk
• Is FDA regulated: No
• Health authority: United Kingdom: National Health ServiceUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

To assess the activity of the FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2 amplified breast, squamous lung and stomach cancer whose cancers have progressed following previous chemotherapy

Description:

Primary endpoint

• To assess anti-tumour activity as change in tumour size at 8 weeks and the correlation with change in tumour ERK1/2 phosphorylation at day 10-14.

Secondary endpoints

• Objective response rate to AZD4547 in all patients and in each tumour group

• Safety and tolerability of AZD4547 in all patients

• Disease control rate at 8 weeks

• Progression free survival in all patients and in each tumour group

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: September 2015
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 25 Years and older

Eligibility

Inclusion criteria

• Female or male aged 25 years or older.

• Mandatory provision of archival or fresh tumour biopsy for confirmation of FGFR gene amplification.

• World Health Organisation performance status 0-2, minimum life expectancy of 12 weeks from proposed first dose date

• Patient ability to comply with the collection of tumor biopsies which is mandatory at baseline and on days 10-14

• Calcium and phosphate within normal limits.

• At least one lesion, not previously irradiated, that can be accurately measured at baseline as >=10 mm in the longest diameter - except lymph nodes which must have short axis >=15 mm.

• Local disease confined to the stomach or oesophagus is not considered measurable (patients with locally advanced gastro-oesophageal adenocarcinoma must have at least one measurable nodal lesion >=15mm in the short axis).

Tumour specific inclusion criteria

Advanced gastro-oesophageal adenocarcinoma

• Histologically proven metastatic or locally advanced inoperable adenocarcinoma of the stomach, lower oesophagus or oesophago-gastric junction.

• Documented progression after 1 or 2 prior courses of chemotherapy for advanced disease,

• FGFR2 amplification

Advanced breast carcinoma

• Histologically confirmed metastatic or locally advanced breast cancer, negative for HER2 as determined by local laboratory.

• Patients with locally advanced disease must have recurrent, or progressive, disease that is not suitable for treatment with curative intent

• Patients with ER positive disease must have been treated with at least one line of hormonal therapy for recurrent/progressive disease or have been on hormonal therapy at the time of recurrence/progression

• Documented progression after at least one and no more than three prior courses of chemotherapy for advanced disease.

• FGFR1 amplification

Advanced squamous cell lung cancer

• Histologically confirmed metastatic or locally advanced squamous cell carcinoma of lung

• Documented progression after 1 or 2 prior courses of chemotherapy for advanced disease

• FGFR1 amplification

Exclusion criteria

• Treatment potent inhibitors or inducers of CYP3A4, 2C8 or 2D6 or substrates of CYP3A4 within specified durations prior to the first dose of study treatment

• Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of study treatment

• Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks before the first dose of study treatment

• Prior exposure to AZD4547 or any other drug with FGFR inhibition as its primary mode of action

• Untreated brain metastases

• Inadequate bone marrow reserve or organ function

• Corrected total calcium > ULN

• Total phosphate > ULN

• Mean resting corrected QT interval > 470 msec obtained from 3 consecutive electrocardiograms (ECGs)

• Any of the following ophthalmological criteria: 1)Current evidence or previous history of retinal pigmented epithelium detachment (RPED). 2)Previous laser treatment or intra-ocular injection for treatment of macular degeneration. 3) Current evidence or previous history of dry or wet age-related macular degeneration. 4) Current evidence or previous history of retinal vein occlusion (RVO). 5) Current evidence or previous history of retinal degenerative diseases (e.g. hereditary). 6) Current evidence or previous history of any other clinically relevant chorioretinal defect

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Carcinoma, Squamous Cell
• Gastric Cancer
• Lung Neoplasms
• Oesophageal Cancer
• Squamous Cell Carcinoma of the Lung

Intervention

Drug:
• AZD 4547

Locations

Country	Name	City	State
United Kingdom	Royal Marsden NHS Foundation Trust	London and Surrey	Surrey

Sponsors (2)

Lead Sponsor	Collaborator
Royal Marsden NHS Foundation Trust	AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess anti-tumour activity as change in tumour size at 8 weeks and the correlation with change in tumour ERK1/2 phosphorylation at day 10-14.	A primary objective of the study is to collect serial research biopsies at baseline and on treatment with AZD4547, to assess the molecular changes that occur in the tumour in response to AZD4547 treatment and correlate with change in tumour size assessed at 8 weeks.	Baseline (tumour size, pERK), day 14(pERK), and week 8(tumour size)	No
Secondary	Response rate	Response rate is assessed using RECIST 1.1 radiological response and centrally reviewed.	Eight weeks from treatment initiation and then every 6 weeks thereafter	No
Secondary	Progression free survival		Time measured from baseline to disease progression or death from any cause (approximately 3-9 months)	No
Secondary	Disease control rate at eight weeks		Disease control rate will be calculated as the proportion of patients with CR/PR/SD at eight weeks from baseline	No
Secondary	Safety and tolerability of AZD4547		Toxicity is assessed from consent until 30 days following treatment cessation	Yes